CCRM Enterprises Inc., CCRM’s for-profit venture investment arm, creates value for regenerative medicine-based technologies and cell and gene therapy companies by making early-stage investments while leveraging CCRM’s sector expertise and specialized infrastructure.

 

CCRM Enterprises invests in early-stage ventures and projects developing therapeutics and enabling technologies. Through an extensive network of investors, it can bring together risk capital to support these early-stage ventures as they scale up along the development pathway. By tapping into CCRM’s manufacturing infrastructure and expertise, CCRM Enterprises provides capital-efficient support to accelerate and de-risk these high potential, early-stage ventures, further enabling the development of an advanced therapies ecosystem.

By leveraging our strong investor network, and with our current and growing access to funds for regenerative medicine-based technologies and cell and gene therapy companies, we can offer start-ups the financial backing to advance their technologies toward commercialization.

International Regenerative Medicine Super Pitch VII: Call for Expressions of Interest

CCRM Global Hubs logoCCRM Enterprises Inc., along with CCRM’s global hubs – CCRM Australia and Sweden-based CCRM Nordic – are together hosting the International Regenerative Medicine Super Pitch VII, which provides developers with an opportunity to pitch to local and international venture capital firms and investors. The International Regenerative Medicine Super Pitch VII offers expertise and investment possibilities for translation and commercializing regenerative medicine and related projects.

Submissions may relate to cell therapies, gene therapies, combination therapies, gene editing tools, enabling technologies such as vector production, automated analytical assays, biosensors, novel media, and other projects related to regenerative medicine in a wide range of therapeutic areas. We welcome submissions from, or affiliated with, Canada, Australia or the Nordic countries.

The International Regenerative Medicine Super Pitch VII will be held online (via Teams) on November 21, 2024.

Canadian companies that are interested in participating or to submit an expression of interest form, please contact Erik Kragegaard, Investment Manager, CCRM Enterprises. For general information or for contacts in other countries, please visit CCRM Nordic’s website.

Gradient line with curved ends

Partnering with start-ups

CCRM works with start-ups to ensure they have the necessary people, facilities and funding. Partnering with start-ups may take the form of direct investment, licensing of technologies to CCRM, or asset co-development.

The core components of our offering to start-ups include:

Development and manufacturing infrastructure

Scientific expertise

Counsel from an expert Investment Board, composed of scientists and venture capitalists

Connection to network and participation in exclusive events

A unique approach as compared to traditional venture capital (VC) groups

Partnering with investors

CCRM also works with other investors in partnerships that may take the form of co-investment in current opportunities, creation of co-branded biotech funds, or direct investments in CCRM’s company creation engine.

CCRM can provide investors with the following: access to local emerging companies or opportunities coming from CCRM’s international hubs; access to our in-house specialized scientific team to inform decisions; and, the potential for engagement with CCRM’s incubating companies.